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Direct quantitative data and corresponding theory are provided for  the effect o f  protein binding 
on the renal transport o f  furosemide. Drug studies were performed with various combinations of  
bovine serum albumin and dextran. This resulted in a percent unbound (fu) of  furosemide ranging 
from 0.785 to 85.8%. The corrected renal (CLr/GFR) and secretion (CLs/GFR) clearances of  
furosemide were observed to increase with percent free, but in a nonproportionaI manner. Plots 
o f  CLr/GFR or CLs/GFR vs. fu appeared to have a prominent y intercept as well as a convex 
ascending curve. In addition, the excretion ratio [ER = CLr/(fu " GFR)]  was reduced from 60.8 
to 8.72 as fu increased. Overall, the data were best fitted to a model in which two Michaelis- Menten 
terms wre used to describe renal tubular transport, and secretion was dependent upon free drug 
concentrations in the perfusate. The results demonstrate that the renal mechanisms o f  furosemide 
excretion are more complex than previously reported and that active secretion may involve two 
different transport systems over the concentration range studied. 
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I N T R O D U C T I O N  
Over the past 10 years, the relationship between the mathematical 
description and biological determinants of hepatic drug clearance has been 
reasonably well defined and experimentally verified. These determinants 
include such factors as hepatic blood flow, the activity of the overall 
elimination process (intrinsic clearance), drug binding in the blood, and 
the anatomic arrangement of the hepatic circulation. On the other hand, 
integration of direct quantitative data and corresponding theory with respect 
to renal drug clearance is rather limited (1-4). In particular, the precise 
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role of changes in plasma protein binding on the secretion kinetics of a 
drug is vague due to the complexity of renal excretion (4-7). 
The proposed studies will systematically evaluate, using the isolated, 
perfused rat kidney, the effect of protein binding on the renal transport of 
furosemide. This diuretic represents a model compound in that it is highly 
plasma protein bound (>90%), demonstrates a net active secretion from 
the renal tubules, and is predominantly eliminated by the renal route in 
humans (8,9). In addition, furosemide is extensively used in various patient 
populations (10-12) and exerts its pharmacodynamic response from the 
luminal surface of the nephron (13-15). Therefore, from a clinical as well 
as a mechanistic standpoint, it is important to determine whether protein 
binding is a limiting factor in furosemide secretion. 
METHODS 
Perfusate 
The initial perfusate volume was 100ml (pH 7.4). It consisted of 
Krebs-Henseleit bicarbonate buffer (16) containing Fraction V bovine serum 
albumin (Miles Laboratories, Elkhart, IN), clinical-grade dextran 
(molecular weight 60,000-90,000; Sigma Chemical Co., St. Louis, MO), or 
a combination of the two, as well as glucose (0.1%), 14C-inulin (2.5/zCi, 
specific activity 2.0/zCi/mg; ICN Biomedicals, Irvine, CA), and eight 
L-amino acids (Sigma Chemical Co., St. Louis, MO) (17). 
Surgical Procedure 
The development of the isolated, perfused rat kidney was based upon 
the methods of Nishiitsutsuji-Uwo et al. (18) and Bowman (19). Male 
Sprague-Dawley rats (Charles River Breeding Laboratories, Wilmington, 
MA), 350-450 g, were anesthetized with sodium pentobarbital ( -50 mg/kg). 
The left superficial femoral vein was exposed and 100 mg of mannitol and 
200 units of heparin were administered. A midline incision was then made 
and the major abdominal blood vessels were isolated. A ligature was passed 
around the right renal artery, and distal and proximal ligatures were placed 
around the mesenteric artery. The right ureter was catheterized with PE-10 
polyethylene tubing. The right renal artery was cannulated via the mesenteric 
artery and the hemostat holding back the perfusate was released just before 
the cannula entered the renal artery. The whole kidney was then excised, 
trimmed of adhering tissue, and immediately transferred to a recirculating 
perfusion apparatus, completely enclosed in a temperature-controlled 
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(37~ Plexiglas chamber. Perfusion pressure in the renal artery was control- 
led by monitoring the manometer and adjusting the speed of the perfusion 
pump. A correction was made for the intrinsic apparatus pressure. 
Experimental Design 
Various combinations of bovine serum albumin (BSA) and dextran 
(D) were used in order to produce a wide range of values for the protein 
binding of furosemide. Two rats were studied at each particular combination 
(6.0% BSA+0% D; 4.0% BSA+l.33% D; 3.0% BSA+2.0% D; 2,0% 
BSA+2.67% D; 1.0% BSA+3.33% D; 0.5% BSA+3.67% D; 0.25% BSA+ 
3.83% D; 0.08% BSA+3.94% D; 0.025% BSA+3.98% D; and 0% BSA+ 
4.0% D) for a total of 20 experiments. The initial perfusate concentration 
of furosemide was 100 tzM. 
After a 20-min equilibration period, furosemide was introduced as a 
bolus into the recirculating perfusate. An additional 20 rain was then allowed 
for drug distribution (2). The subsequent experimental time was divided 
into 10-min urine collection periods for the measurement of kidney function 
and drug disposition parameters. The urine volume was measured with a 
tuberculin syringe and the pH was determined immediately. Perfusate 
(1.5 ml) was sampled at the midpoint time of each urine collection. The 
composition of recirculating perfusate was maintained by isovolumetric 
replacement of urine loss with buffer and perfusate sampling loss with 
perfusate (no drug present). Kidney function was determined by the frac- 
tional excretion of sodium and glucose, and by glomerular filtration rate 
(GFR). The renal clearance of inulin was taken to represent GFR. Renal 
clearances were calculated for furosemide and inulin by dividing the urinary 
excretion rate of the substance by its perfusate concentration at the midpoint 
time interval. 
Analytical 
Perfusate and urine samples containing furosemide were analyzed by 
a sensitive and specific HPLC assay developed by Smith et aL (20), This 
method utilizes a direct injection technique where the only cleanup pro- 
cedure involves the precipitation of albumin with acetonitrile. Representa- 
tive urine samples were also analyzed for the glucuronide metabolite of 
furosemide and 2-amino-4-chloro-5-sulfamylanthranific acid (CSA), as 
described previously (20). This is necessary since intrarenal metabolism can 
obscure the correct interpretation of renal clearance mechanisms (6). These 
assays were modified to reflect the smaller volume requirement (0.05 ml) 
for perfusate and urine samples obtained during the isolated, perfused rat 
kidney experiments. 
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Radioactivity measurements for 14C-inulin were performed on an 
LS 9000 liquid scintillation counter (Beckman Instruments, Irvine, CA) 
using an external standard method for quench correction. Sodium was 
determined with a model 455 flame photometer (Corning Medical and 
Scientific, Medfield, MA) and glucose was determined colorimetrically using 
a commercial kit (Sigma Chemical Co., St. Louis, MO). 
Protein Binding 
The binding of furosemide to albumin in the recirculating perfusate 
was determined using an equilibrium dialysis method (20,21). One-half ml 
of perfusate was dialyzed against an equal volume of isotonic phosphate 
buffer (0.067 M, pH 7.4) at 37~ for 5 hr using Spectrapor 2 membrane 
tubing (Spectrum Medical Industries, Los Angeles, CA). Preliminary studies 
indicated that 5 hr was a sufficient amount of time for equilibrium to be 
reached at the various albumin concentrations employed in these experi- 
ments. Dialyzed buffer (0.3 ml) was then mixed with the internal standard, 
sodium phenobarbital, and injected into the HPLC system, as described 
previously (20). 
Furosemide exhibited a nonlinear binding in several experiments and 
values for percent free were determined accordingly (22,23). Since the initial 
volumes of the perfusate and buffer compartments were equal prior to 
dialysis, the volume-corrected bound concentration in the post dialysis 
perfusate (Cb") was calculated as 
Cb"= Cp-2.  Cf' (1) 
where Cp represents the measured total plasma concentration of furosemide 
prior to dialysis and Cf' represents the measured unbound concentration 
of furosemide in buffer after dialysis. This equation was developed to correct 
for the osmotic water shift that occurs during equilibrium dialysis, resulting 
in lower protein and bound drug concentrations in the postdialysis plasma 
compartment (23). 
The appropriate bound (Cb") and free (Cf') equilibrium concentrations 
of furosemide were then best-fitted to a protein binding model which 
incorporates a single Langmuir term plus two linear terms: 
P~. BSA. Cf' 
Cb"- bP 3 9 BSA. Cf'+P4(870-BSA). 0.561Cf' (2) 
P2+ Cf' 
P1, P2, P3, and P4 represent the binding parameters, BSA represents the 
concentration of bovine serum albumin, and (870-BSA) 9 0.561 represents 
the concentration of dextran in the perfusate for a given concentration of 
BSA, expressed in/xM units. Dextran was included in the binding model 
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since in vitro experiments confirmed that approximately 10-15% of 
furosemide is bound to 4% of this polymer. 
Once the binding parameters are known, the unbound (Cf) and bound 
(Cb) concentrations in the original perfusate sample can be determined by 
simultaneous solution of Eq. (2) and the relationship Cp = Cf+ Cb (22). 
This results in the equation 
[ I + BSA.  PB + P4(870- BSA) o 0.561]Cf z 
+ [P2+ BSA.  P, + BSA.  P2Pa + P2P,(870 - BSA) .  0.561 - Cp]Cf 
-P2Cp =0. (3) 
in which Cf can be obtained by finding the positive root of the quadratic 
equation (3) for given values of Cp and BSA. 
The percent of unbound furosemide in the original recirculating perfu- 
sate can now be determined by 
fu (%) = lO0(Cf/Cp) (4) 
R e n a l  Transport  M o d e l s  
For a compound of low extraction (plasma flow to the kidney >> intrinsic 
renal tubular secretion), Levy (4) proposed the following models to express 
the relationship between renal drug clearance (CLr) and free fraction (fu): 
C L r : f u .  [GFR. ( 1 - F ) + K s .  ( 1 - F ) ]  (5) 
CLr=fu .  GFR. (1 - F ) +  Ks' ,  ( 1 - F )  (6) 
where F represents the tubular reabsorption fraction, Ks the renal tubular 
secretion clearance referenced to unbound drug concentrations in plasma, 
and Ks' the renal tubular secretion clearance referenced to total drug 
concentrations in plasma. Both equations assume that renal tubular secretion 
remains linear over the concentration range studied and that the tubular 
reabsorption fraction is constant and involves the passive diffusion of 
nonionized drug molecules from the distal region of the renal tubules. 
Accordingly, if the rate of renal tubular secretion is a function of the 
unbound drug, then a plot of renal clearance versus free fraction in plasma 
should be linear and intersect the origin [Eq. (5)]. If the rate of renal tubular 
secretion is a function of the total drug, then a plot of renal clearance versus 
free fraction should be linear and have a positive intercept [Eq. (6)]. 
However, application of these relationships to furosemide revealed that 
Eqs. (5) and (6) were not appropriate to describe our data (see results). 
Therefore, the theoretical models below were derived. 
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In general, the excretion of a drug from the plasma into the urine is 
expressed by 
U. V = GFR . Cf + S - A (7) 
where U is the drug concentration in urine, r~ is the urine flow rate, S is 
the rate of secretion, and A is the rate of reabsorption. By assuming that 
two Michaelis-Menten terms are needed to describe a drug's rate of active 
secretion, and that secretion is dependent upon free drug concentrations, 
we can express S and A by 
Vml" Cf Vm 2 9 Cf 
s ~ (8) 
Kml + Cf Km2 + Cf 
A = F(GFR.  Cf+ S) (9) 
where Vm~ and Krnl are the maximum velocity of secretion and the 
Michaelis constant, respectively, for the low-affinity, high-capacity transport 
system, and Vm2 and Kin2 are the maximum velocity of secretion and the 
Michaelis constant, respectively, for the high-affinity, low-capacity transport 
system. Therefore, the renal clearance becomes 
Vm, . fu  ~- V m 2 . f u ~ ( l _ F )  (10) 
CLr = GFR . fu q Kin1 + Cf Kin2 + Cf ] 
The excretion ratio (ER) is then obtained by dividing each side of Eq. 
(10) by fu .  GFR, 
Vml/GFR Vm2/GFR~ 
ER= 14 Km~+Cf ~ ~ / ( 1 - F )  (11) 
Since the second transport system is of a high-affinity, low-capacity nature, 
Cf >> Kin2, and Eq. (11) simplifies to 
( Vm2/GFR) 1 ER = 14 Vm~/GFR ~- ( - F )  (12) 
Kml + Cf - ~  " 
The urinary excretion rate (U.  r~) was derived by substituting S [Eq. 
(8)] and A [Eq. (9)] into Eq. (7) and then applying the same assumptions 
as in Eq. (12) (Cf>> Km2): 
U - i ? = ( G F R .  Cf 4 
Statistical Analysis 
Vrn 1 9 cf \ Jr Vm2] (1 - F )  (13) 
Kml + Cf / 
Experimental data were fitted to Eqs. (2), (12), and (13) using the 
nonlinear least-squares regression program NONLIN (24). The parameter 
estimates (+standard deviation) were obtained using a weighting factor of 
unity and the goodness of the fit was determined by R 2, COR, and by visual 
examination of the residuals. 
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Table I. Physiological Function of the Isolated Perfused Rat Kidney ~ 
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Parameter value at given concentration of BSA b 
6% 4% 3% 2% 1% 0.5% 0.25% 0.08% 0,025% 0% 
GFR 0.995 0.844 0.816 0,880 0.847 0.594 0.777 0.779 0.670 0.576 
(ml/min) (0.136) (0.081) (0.198) (0.262) (0,123) (0.081) (0.198) (0.078) (0.109) (0.095) 
FEsodium 16.5 13.3 16,1 13.8 11.6 18.4 10,9 ~ 15A 16,0 22.8 
(%) (1,9) (4.7) (6.2) (5.6) (3.0) (1.7) (3.9) (3.2) (1.5) (2.8) 
FEglucose 1.70 4.59 3.43 4.14 5.33 4.69 3.59 5.54 5.31 7.91 
(%) (0.43) (1.53) (2.27) (2.25) (2.67) (0.93) (1.08) (1.16) (0.64) (1.39) 
Perfusate flow 42.8 35,4 34.2 24.8 23.9 23.0 27.5 24.6 24.7 27.8 
(ml/min) (4.3) (5.5) (1.2) (1.1) (1.7) (0.13) (5.4) (0.2) (0.1) (2.2) 
Perfusion 91.8 95.6 96.4 97.5 93.3 98.8 93.7 94.6 96.1 94.6 
pressure (1.2) (1.3) (6.6) (2.2) (1.7) (7.2) (3.5) (4.0) (6.4) (1.6) 
(ram Hg) 
N c 15 18 17 14 18 18 15 16 14 10 
"Data reported as mean • 
bFurosemide was present in the perfusate at an initial concentration 
the perfusate as indicated in Table II. 
CNumber of clearance periods studied in two rat perfusions. 
of 100~M. Dextran was present in 
RESULTS 
Physiological Function of the Perfnsed Kidney 
Presented in Table I are the functional characteristics of perfusate 
experiments containing furosemide when carried out at various 
albumin/dextran combinations. Kidney function as reflected by GFR and 
fractional glucose excretion (FEglucose) were within the normal range of 
values for this technique (2,3,17,25), although a general reduction of GFR 
and perfusate flow was observed as dextran concentrations became greater. 
Since furosemide is a "loop-diuretic," a fractional sodium excretion 
(FEsodium) of 12-23% is to be expected (26). Nevertheless, the proximal 
tubule retains considerable capacity for transport, as evidenced by the 
relatively low values for FEglucose in all experiments (1). Predrug func- 
tional parameters were 0.988ml/min (GFR), 7.55% (FEsodium), and 
0.96% (FEglucose) at 6% BSA+0% D; and 0.722 ml/min (GFR), 7.97% 
(FEsodium), and 2.34% (FEglucose) at 0% BSA+4% D. 
Protein Binding 
Using the input values of Cb" as the dependent variable and BSA and 
Cf' as the two independent varibles, the binding parameters of Eq. (2) were 
estimated as P~ =0.44 (0.14), P2 = 2.92 (0.86)/~M, P3 =0.022 (0.013)/xM -1, 
and P4=0.00034 (0.00020) /zM -t (R2=0.980; COR=0.975). The para- 
meter estimates and the application of Eqs. (3) and (4) allowed for the 
calculation of the percent unbound of furosemide in the original perfusate 
samples. Table II demonstrates that the percent unbound of furosemide 
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Table II. Composition of  Perfusate and Corresponding 
Fraction Unbound of Furosemide" 
BSA Dextran Fraction unbound 
(%) (%) (%) 
6 0 0.785 
(0.056) 
4 1.33 1.24 
(0.06) 
3 2.00 1.74 
(0.11) 
2 2.67 3.04 
(0.26) 
1 3.33 6.51 
(1.28) 
0.5 3.67 15.4 
(3.8) 
0.25 3.83 26.2 
(7.2) 
0.08 3.94 48.2 
(10.8) 
0.025 3.98 72.9 
(4.4) 
0 4 85.8 
(0.0) 
a Data reported as mean +SD. Fraction unbound was deter- 
mined for each clearance period of  the recirculating perfu- 
sate. Furosemide was present initially at a concentration 
of  100/~M. Refer to Table I for number of  clearance 
periods studied in each group. 
could be manipulated from very low values (0.785%) to almost 90% free 
drug under the albumin/dextran concentrations employed. 
Furosemide Metabolism 
Using a specific HPLC assay, we were unable to detect a glucuronide 
metabolite of furosemide or CSA in any of the samples tested. This lack 
of biotransformation or degradation during the kidney perfusion experi- 
ments is in agreement with a similar study where at least 97% of the 
radioactivity present in perfusate or urine samples was reported as 
unchanged furosemide (2). 
Furosemide Excretion 
In Table III, clearance values have been corrected for GFR to take 
into account the varying functional capacity among kidney preparations. 
The corrected renal and secretion clearances of furosemide are observed 
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Table III. Furosemide Clearance in the Perfused Rat Kidney" 
BSA 
(%) CLr/GFR CLs/GFR CLr/fu. GFR 
6 0.472 0.464 60.8 
(0.057) (0.057) (10.7) 
4 0.512 0.500 41.7 
(0.074) (0.072) (6.9) 
3 0.605 0.586 35.5 
(0.197) (0.197) (14.1) 
2 0.718 0.691 23.6 
(0.203) (0.203) (7.5) 
1 1.32 1.25 21.2 
(0.31) (0.31) (7.1) 
0.5 2.36 2.22 16.6 
(0.48) (0.48) (6.3) 
0.25 4.17 3.94 17.1 
(0.90) (0.93) (6.7) 
0.08 7.10 6.55 15.9 
(1.88) (1.92) (6.2) 
0.025 11.2 10.5 15.7 
(3.4) (3.4) (5.4) 
0 7.48 6.55 8.72 
(1.29) (1.27) (1.50) 
~Data reported as mean • Dextran was present in the perfusate 
as indicated in Table If. Furosemide was present at an initial con- 
centration of 100/.t M. Number of clearance periods studied in each 
group is shown in Table I. CLr/GFR represents the renal clearance 
of furosemide corrected for glomerular filtration rate. CLs/GFR 
represents the secretion clearance of furosemide corrected for 
glomerular filtration rate (CLs/GFR was calculated as CLr/GFR - 
fu). CLr/(fu. GFR) represents the excretion ratio, which is the renal 
clearance of furosernide corrected for the fraction unbound in the 
perfusate and glomerular filtration rate. 
to increase as the u n b o u n d  fract ion increases.  However,  they do so in a 
n o n p r o p o r t i o n a l  manne r ,  implying  that the renal  t ranspor t  of  furosemide  
may be compl ica ted  by a capacity-l imited secretory component .  This f inding 
is further  suppor ted  by the values for excret ion ratio, which indicate  a 
reduct ion  in  net  secret ion (from 60.8 to 8.72) as the fract ion u n b o u n d  
becomes greater. Pre l iminary  inspect ion  of the data revealed that  the renal  
mechanisms  of  furosemide  t ranspor t  may be even more complex (Figs. 1 
and  2). Both Figs. 1 and  2 appear  to have a p r omi ne n t  y intercept  as well 
as a convex ascending  curve. To be consis tent  with the under ly ing  assump- 
t ions of  Eq. (5) or (6), a plot  of  secretion clearance versus percent  free 
would  have to be a straight l ine with a zero y intercept  or remain  a cons tant  
Value, respectively. This led us to suspect that  the renal  tubu la r  secret ion 
of  furosemide  may involve two different t ranspor t  mechanisms  over the 
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F R A C T I O N  U N B O U N D  O F  F U R O S E M I D E  ( % )  
Fig. 1. Relationship between corrected renal clearance (CLr/GFR) and 
fraction unbound (fu) of  furosernide in the isolated, perfused rat kidney. 
Each point represents the mean • SD of clearance periods for each experi- 
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F R A C T I O N  U N B O U N D  OF F U R O S E M I D E  (%)  
Fig. 2. Relationship between corrected secretion clearance (CLs/GFR) and frac- 
tion unbound (fu) of  furosemide in the isolated, perfused rat kidney. Each point 
represents the mean • SD of clearance periods for each experimental group (refer 
to Tables II and III). 
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concentration range studied. The experimental evidence in support of  this 
hypothesis is presented below. 
The relationship between excretion ratio and unbound concentration 
of  furosemide in the isolated, perfused rat kidney is shown in Fig. 3. Using 
the input values ER and Cf we estimate the unknown parameters of  Eq. 
(12) (Vml/GFR as PI, Km~ as P2, and Vm2/GFR as P3;  F = 0 ;  see 
discussion) as P~=357 (190)/xM, Km1=27.1 (17.6)/zM, and / '3=22.5 
(1.5) brM (R 2= 0.940; COR = 0.888). The values of Vml (278 nmole/min)  
and Vrn2 (17.5 nmole/min)  were calculated by multiplying P1 and P3 by 
the mean value for GFR (0.778 ml/min).  As observed in Fig. 3, the data 
are compatible with the proposed model in which furosemide secretion is 
described by two distinct transport processes. 
The data were also fitted to Eq. (13), in which the relationship between 
urinary excretion rate and unbound concentration of furosemide in the 
isolated, perfused rat kidney was examined (Fig. 4). Using the input values 
U. V and Cf and a mean value of 0.778 ml/min for GFR in the right side 
of  the equation, we estimate the unknown parameters (Vm I as P~, Km~ as 
/2 ,  and Vm2 as P3; F = 0; see discussion) as Vml = 300 (53.9) nmole/min,  
Kml = 39.8 (12.4)/~M, and Vm2 ---- 22.1 (2.7) nm01e/min (R 2 -- 0.937; CaR = 
0.917). Application of Eq. (13) resulted in smaller coefficients of variation 
than Eq. (12) for P~ a n d / 2 ,  but not P3- These differences probably reflect 
the inherent bias produced by data transformation and consequently weight- 
ing. Still, both of  these equations (12) and (13) afforded reasonable estimates 
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UNBOUND CONCENTRATION OF FUROSEMIDE (UM) 
Fig. 3. Relationship between excretion ratio (ER) and unbound concentration 
of furosemide (Cf) in the isolated, perfused rat kidney. All 155 clearance 
periods from 20 experiments are depicted. The solid line represents the 
computer-simulated curve based on the fitted parameters of Eq. (12). 




I 9 " " 
~) I 9 / ~  9 
~ 9 ~ 
so  aIF2. "" " 
0 O e  
z 
-- 0 5 i0 15 20 25 30 35 40 45 50 
UNBOUND CONCENTRATION OF FUROSEMIDE (UM) 
Fig. 4. Relationship between urinary excretion rate (U.  I~') and unbound 
concentration of furosemide (Cf) in the isolated, perfused rat kidney. All 
155 clearance periods from 20 experiments are depicted. The solid line 
represents the computer-simulated curve based on the fitted parameters of 
Eq. (13). 
of the renal transport parameters of furosemide and support the hypothesis 
that furosemide secretion may be operating by two different mechanisms. 
While an equivalent mathematical relationship can be derived for the 
high-affinity, low-capacity transport term in Eq. (12) or (13) when the driving 
force is total drug, this theory is inconsistent with the data recently reported 
by Hall and Rowland (2). 
DISCUSSION 
Utilizing the isolated, perfused rat kidney, Bowman (1) demonstrated 
that the ability of the renal secretory mechanism to extract 35S-labeled 
furosemide from the perfusate was closely related to the concentration of 
unbound drug. At a perfusate concentration of 500/zM furosemide, 
secretion of the drug was doubled when the albumin concentration was 
decreased from 7.5 to 5 g/100 ml (corresponding to a percent unbound of 
2.19 and 3115, respectively). Secretion was again doubled when the albumin 
concentration was further decreased to 2.5 g/100ml (corresponding to a 
percent unbound of 9.4). Although these changes in net furosemide secretion 
are in the same direction as changes in percent unbound, they are not always 
of the same magnitude. Similar findings were reported by Koschier and 
Acara (3) when studying the transport of ~4C-labeled trichlorophenoxyace- 
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tate (2,4,5-T) in the isolated, perfused rat kidney. These authors concluded 
that the secretion of 2,4,5-T appears to be hindered by plasma protein 
binding. At an initial perfusate concentration of 1.86/~ M, the 2,4,5-T/inulin 
clearance ratio increased over 300-fold [from 0.019 in BSA (6%) perfusate 
to 6.16 in dextran (4%) perfusate] when the percent free increased 150-fold 
(from 0.46 to 70.7). Again, a nonproportional change was observed between 
the extent of plasma protein binding and the renal clearance of 2,4,5-T, as 
was the case for furosemide. These findings may reflect the fact that perfusion 
experiments were performed with a limited number of free fraction values 
(1) or only at the extremes of protein binding (3). Renal tubular secretion 
may also be exhibiting capacity-limited transport at the concentrations being 
studied (1). 
Recently, Hall and Rowland (2) reported data on the renal and secretion 
clearances of [14C]furosemide, referenced to total and unbound drug con-  
centrations, in the isolated, perfused rat kidney. Using various combinations 
of albumin and dextran, these investigators observed a linear relationship 
between the renal clearance of furosemide and free fraction. Furthermore, 
when the fraction unbound was zero, the y intercept was not significantly 
different from zero. Their data are consistent with the model expressed by 
Eq. (5), and support the view that for drugs that are actively secreted and 
of low renal extraction, the renal and secretory clearances are directly 
proportional to the fraction unbound. As a result, the excretion ratio of 
furosemide, which averaged approximately 4.6, was relatively constant over 
the 28-fold range of free fraction values, indicating a linear secretory 
mechanism. Discrepancies between our study and that of Hall and Rowland 
(2) probably reflect the fact that different concentrations of furosemide were 
employed. In our study, initial perfusate samples contained 100/zM of 
furosemide, whereas very low and nonpharmacologic concentrations of 
furosemide (<5/zM) were perfused in the study by Hall and Rowland (2). 
In addition, the latter study did not correct for the volume shifts that can  
occur during equilibrium dialysis (23), thereby causing systematic errors in 
the furosemide free fraction. Although we show a similar dependence of 
renal drug transport on free concentrations of furosemide, our data were 
complicated by the presence of capacity-limited secretion and by the appear- 
ance of more than one secretory transport system. 
As previously mentioned, we observed a general reduction in G F R  
and perfusate flow in our experiments at lower albumin concentrations. 
Bowman et al. (27) in perfused rat kidneys and Duarte et al. (28) in 
micropuncture experiments in the rat also showed a fall in G F R  as 
furosemide reached the urine in pharmacologically significant concentra- 
tions. Although both investigators state that the reason for the decline in 
G F R  is unclear, they suggest that it may be due to an increased intratubular 
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pressure which develops after the drug-induced reduction in tubular sodium 
and fluid reabsorption. However, in our studies the fractional sodium 
excretion was relatively constant as a function of albumin concentration, 
making this an unlikely explanation for the observed attenuation in GFR. 
Alternatively, it is possible that increasing amounts of urinary furosemide 
caused a redistribution ofintrarenal blood (perfusate) flow to the midcortical 
nephrons (29,30). This could result in a reduction in the number of function- 
ing nephrons, since this region comprises only 30% of the total nephron 
population (31). Nevertheless, clearance values (CLr/GFR, CLs/GFR, 
ER) were corrected for GFR to take into account the varying functionality 
between kidney preparations. This approach to the treatment of the data 
minimizes the chance of the two-component active secretory system being 
a result of declining renal function. Further support for the validity of our 
model (i.e., two different transport systems for active secretion) is afforded 
when the furosemide data of Bowman (1) are superimposed upon the 
computer-generated regression line of Eq. (12). As shown in Fig. 5, the 
curves are remarkably similar even though a different study design and 
assay method were employed during the perfusion experiments. It should 
be noted that either no change or an increase in GFR was observed by 
Bowman (1) as the percent albumin was reduced. 
Previous studies by Hori and co-workers (32-34) demonstrated that 
the renal tubular secretion of phenolsulfonphthalein, sulfamethizole, sul- 
famethoxazole, cephalexin, and ampicillin correlates with unbound drug 
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Fig. 5. Furosemide data of  Bowman (1) superimposed upon the computer- 
generated regression line of  Eq. (12) (see Fig. 3). 
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Michael is-Menten term describes renal tubular  transport,  and secretion rate 
is dependent  upon free concentrations of  drug in the plasma: 
Vm/ GFR . 
ER = (1-~ ~ m ~ )  ( l - F) (14) 
Our results did not fit this model very well, as shown in Figs. 6 and 7. Using 
different initial estimates for the renal transport  parameters,  the computer-  
fitted curves displayed a marked and systematic deviation from the data in 
addition to having greater values for the residual sum of squares (61,578 
in  Fig. 6A and 10,824 in Fig. 6B versus 8869 in Fig. 3; 8423 in Fig. 7 versus 
6270 in Fig. 4). The discrepancy between our study with furosemide and 
those of Hori  and co-workers (32-34) may reflect the different drugs 
examined. However,  the unbound concentrations in their studies ranged 
from approximately 30 to 1500/zM, a value where the influence of  the 
high-affinity, low-capacity transport  system is minimal at best. Therefore, 
they may have been unable to detect, if existent, this second transport  system. 
Interpretation of  the data is based on the assumption that the reabsorp- 
tion fraction F remains constant during and between experiments. In our 
analysis of  the furosemide data we assumed that F was equal to zero. This 
was done for several reasons. First, Bowman (1) demonstrated that in the 
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Fig. 6. Computer-generated regression curves of Eq. (14) (one Michaelis- 
Menten term used to describe secretion) superimposed upon the furosemide 
excretion ratio data of Fig. 3. The lines A and B were obtained using different 
initial estimates for the renal transport parameters. 
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Fig. 7. Computer-generated regression curve using only a single Michaelis- 
Menten term in Eq. (13) for describing the active secretion of furosemide. 
This line was superimposed upon the furosemide excretion rate data of 
Fig. 4. 
of  furosemide to that expected from filtration alone. This suggests that the 
extent of  furosemide reabsorption is minimal at best in the isolated, perfused 
rat kidney. Second, we also fitted our data to the transport  models expressed 
by Eqs. (12) and (13) where F was allowed to be an unknown parameter.  
Regardless of  the initial estimates provided, F was computed as zero. Third, 
at the urinary p H  values observed in our studies (mean of  6.9; CV of  5.5%) 
and given that the pKa of  furosemide is 3.9 (35), the fraction of total drug 
nonionized would be insignificant. These facts, plus the lack of either a 
urine flow or p H  effect on furosemide renal clearance, indicate that in these 
experiments reabsorption is not a significant mechanism of renal t ransport  
for this drug (2). 
The present study has at tempted to integrate quantitative data with a 
corresponding model  for the renal transport  of  furosemide. Our results 
demonstrate  that the renal mechanisms of  furosemide excretion are more 
complex than previously reported (1,2). Specifically, we show that the renal 
tubular secretion of furosemide may involve two different transport  mechan- 
isms over the concentration range studied. One secretory site is consistent 
with a high-affinity, low-capacity transport and the other with a low-affinity, 
high-capacity transport.  Although speculative, these different transport  
mechanisms may reflect the morphological  and functional heterogeneity of  
the proximal  tubule cells (36,37). 
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